CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 11 enrolled
Drug / intervention
memantine +1 moredrug
Likely dose
Memantine-containing capsule starting the day before ECT begins and during ECTAI-extracted
Key inclusion· 4
  • ✓Meets DSM-IV criteria for Major Depressive Disorder
  • ✓Ages 18 to 75 and able to provide legal consent
  • ✓Referred to Stanford ECT service by treating physician for unilateral electroconvulsive therapy with inpatient hospitalization
  • ✓Completed consent process for clinical ECT use according to California State law
Key exclusion· 9
  • ✕ECT treatment in the 6 months prior to screening
  • ✕Meets criteria for drug or alcohol abuse or dependence in the 6 months prior to screening
  • ✕Use of alcohol or illegal drugs within seven days of randomization or during study
  • ✕Unstable or untreated cardiovascular disease, hypertension, or endocrine disorder

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00186498
NCT00186498N/ACompleted
CompareCT.gov

Memantine as an Adjunctive Agent to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Severe Major Depressive Episode

Stanford University·interventional·Posted Sep 16, 2005·Updated Sep 27, 2019

In Brief

A clinical study evaluating memantine and Placebo Oral Capsule for Depressive Disorder, Major. Completed, enrolled 11 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether taking the medication memantine reduces impairment of memory and attention associated with electroconvulsive therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder, Major
CountriesUnited States
CollaboratorsForest Laboratories

Timeline

N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 16, 2005
Enrollment StartFeb 1, 2004
Primary CompletionFeb 1, 2006
Study CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 20.8 years ago

Interventions

memantinedrug

Patients received a memantine containing capsule starting the day before ECT begins and while receiving ECT

Placebo Oral Capsuledrug

Patients received a placebo capsule starting the day before ECT begins and while receiving ECT